AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2018

Dec 7, 2018

30610_dirs_2018-12-07_a8b3f0b3-4ada-4694-b2cc-82144c30caff.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2018-12-07

Reporting Person: HENDERSON LORI M. (General Counsel and Secretary)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$14.85	2028-06-26	Common Stock (527522)		Direct

Footnotes

F1: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.